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Abstract: A series of novel guanylhydrazones were designed, synthesized and 
characterized. All the compounds were screened for their antibacterial and anti-
fungal activity. Compounds 26 and 27 showed excellent antibacterial activities 
against Staphylococcus aureus ATCC 25923 and Micrococcus luteus ATCC 
379 with minimal inhibitory concentrations of 4 µg mL-1, and good antifungal 
activity against Candida parapsilosis ATCC 22019. These results suggested 
that the selected guanylhydrazones could serve as promising leads for imp-
roved antimicrobial development. 
Keywords: guanylhydrazones; iminoguanidines; antibacterial activity; antifun-
gal activity; Candida spp. 
INTRODUCTION 
Infectious diseases caused by human pathogens, both bacteria and fungi, 
result in significant morbidity and mortality worldwide. Treatment of these dis-
eases is often hampered by limited therapeutic options and the development of 
resistance. Bacteremia is a major cause of life-threatening complications in 
patients in intensive care units, neonates, or cancer patients, who are at extremely 
high risk for infections caused by antibiotic resistant bacteria.1 Invasive candi-
diasis is the fourth most common bloodstream infection with mortality rates 
remaining disturbingly high at 40 %.2 This makes the quest for new molecules 
that are effective against the threat of drug resistance a significant issue in mod-
ern medicine. 
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Guanylhydrazones have been a long-standing point of interest in medicinal 
chemistry.3 Recently, a two-step procedure was demonstrated for the preparation 
of simple guanylhydrazones 1 (Fig. 1).4 The synthesized compounds were eva-
luated for their in vitro antifungal activities against a wide range of medically 
important fungal strains. Among the series, compound 2 proved to be an effect-
ive, broad-spectrum antifungal compound (Fig. 1). In particular, compound 2 
exhibited excellent activity against the voriconazole-resistant Candida albicans 
CA5 strain.  
Given the good antifungal properties shown by selected guanylhydrazones 
and as a continuation of research on the development of new antimicrobial agents, 
in the present work, the synthesis, characterization and evaluation of the antibac-
terial and antifungal properties of new guanylhydrazone derivatives are reported. 
 
Fig. 1. Guanylhydrazones. 
RESULTS AND DISCUSSION 
Chemistry 
The Suzuki–Miyaura reaction enabled access to a range of aldehydes 4–7 
from easily obtainable starting compounds (Scheme 1). The low yield of alde-
hyde 5 is associated with problems during purification and isolation of the 
desired product from the crude reaction mixture. The reported yield is also non- 
-optimized and certainly could be further improved through variation of the 
reaction conditions. 
 
Scheme 1. Synthesis of aldehydes 4–7. 
Bromination of aldehydes 85 and 9 with bromine and N-bromosuccinimide 
afforded the corresponding monobromo derivatives 10 and 11, respectively 
(Scheme 2). Aldehydes 12 and 13 were prepared by a Suzuki–Miyaura reaction 
starting from bromide 10 (Scheme 2). Access to 4-fluoro-5-phenyl-2-furaldehyde 
(15) was accomplished by a halogen/metal exchange reaction. The lithiated inter-
mediate formed in the reaction medium was trapped with the electrophilic fluor-
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inating reagent N-fluorobenzenesulfonimide (NFSI, Scheme 2). The thiophene 
aldehyde 8 underwent nitration with a mixture of nitric acid and acetic anhydride 
affording the corresponding 4-nitro derivative 16 in 71 % yield (Scheme 2). 
Subsequent acid hydrolysis of 16 gave the nitroaldehyde 17 (Scheme 2). 
 
Scheme 2. Synthesis of aldehydes 10–13, 15 and 17. 
The guanylhydrazones 18–27 were synthesized using a one-step conden-
sation reaction of aminoguanidine hydrochloride and the corresponding aldehyde 
in good to excellent yields (Scheme 3). All the guanylhydrazones were obtained 
as hydrochlorides. 
 
Scheme 3. Synthesis of guanylhydrazones 18–27. 
Antimicrobial activity 
All synthesized guanylhydrazones were assessed for their antimicrobial act-
ivity against one Gram-negative strain (Pseudomonas aeruginosa PAO1, NCTC 
10332), and three Gram-positive strains (Staphylococcus aureus ATCC 25923, 
Micrococcus luteus ATCC 379 and Listeria monocytogenes NCTC 11994) and 
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three fungal strains (Candida albicans ATCC 10231, Issatchenkia orientalis 
ATCC 6258 and Candida parapsilosis ATCC 22019). The minimum inhibitory 
concentration (MIC) values obtained by the standard broth dilution method were 
compared to those of clinically used antibiotics (kanamycin and nystatin). 
Most of the tested compounds were found to display poor to moderate act-
ivities against the tested bacterial strains, with the exception of compound 22, 
which displayed excellent antibacterial activity against P. aeruginosa PAO1, and 
compounds 26 and 27, which exhibited excellent activities against S. aureus 
ATCC 25923 and M. luteus ATCC 379 (Table I). It is noteworthy that com-
pounds 22, 26 and 27 showed better antibacterial activities against these three 
bacterial strains in comparison to the control drug, kanamycin (Table I). 
TABLE I. Minimal inhibitory concentrations, MIC / µg mL-1 
Compound P. aera S. aurb M. lutc L. mond C. albe I. orif C. parg 
18 150 62.5 62.5 125 50 62.5 31.2 
19 200 125 31.2 500 250 125 62.5 
20 125 62.5 125 250 200 125 62.5 
21 >500 15.6 125 >500 31.2 62.5 31.2 
22 4 62.5 62.5 125 125 100 62.5 
23 >500 125 15.6 15.6 31.2 31.2 15.6 
24 250 62.5 62.5 62.5 62.5 18.8 31.2 
25 >500 >500 >500 >500 62.5 62.5 31.2 
26 >500 4 4 >500 15.6 15.6 6 
27 >500 4 4 >500 31.2 31.2 6 
Kanamycinh 50 10 12.5 12.5 – – – 
Nystatinh – – – – 1 7.8 2 
aPseudomonas aeruginosa PAO1 NCTC 10332; bStaphylococcus aureus ATCC 25923; cMicro-
coccus luteus ATCC 379; dListeria monocytogenes NCTC 11994; eCandida albicans ATCC 
10231; fIssatchenkia orientalis ATCC 6258; gCandida parapsilosis ATCC 22019; hcontrol drug 
From a perusal of the data, it could be seen that all the tested compounds 
showed moderate antifungal activity against all the tested fungal strains, while 
two compounds 26 and 27 exhibited the most promising activity against C. 
parapsilosis ATCC 22019 (Table I). 
Overall, the minimal inhibitory concentrations (MIC) values lead to the con-
clusion that the additional aromatic ring on thiophene was beneficial to the anti-
bacterial and antifungal activity of compounds 26 and 27. 
EXPERIMENTAL 
Instrumentation 
Dry-flash chromatography was performed on SiO2 (0.018–0.032 mm). Melting points 
were determined on a Boetius PMHK apparatus and were not corrected. IR spectra were rec-
orded on a Thermo-Scientific Nicolet 6700 FT-IR Diamond Crystal instrument. 1H- and 13C- 
-NMR spectra were recorded on a Bruker Ultrashield Advance III spectrometer (at 500 and 
125 MHz, respectively) using tetramethylsilane (TMS) as the internal standard. Chemical 
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shifts are expressed in ppm (δ) values and coupling constants (J) in Hz. ESI MS spectra of the 
synthesized compounds were recorded on an Agilent Technologies 6210 time-of-flight LC– 
–MS instrument in the positive ion mode using MeOH/H2O = 1/1 with 0.2 % HCOOH as the 
carrying solvent solution. The samples were dissolved in pure MeOH (HPLC grade). The sel-
ected settings were as follows: capillary voltage, 4 kV; gas temperature, 350 °C; drying gas, 
N2, 12 L·min-1; nebulizer pressure, 45 psig*; fragmentator voltage, 70–200 V. The GC–MS 
spectra of the synthesized compounds were acquired on an Agilent Technologies 7890A appa-
ratus equipped with a DB-5 MS column (30 m×0.25 mm×0.25 μm), a 5975C MSD and FID 
detector. Selected settings were as follows: carrier gas He (1.0 mL min-1), temperature linearly 
increased from 40–315 °C (10 °C min-1), injection volume, 1 μL, temperature, 250 °C, tempe-
rature (FID detector), 300 °C, and EI mass spectra range: m/z 40–550. Thin-layer chromato-
graphy was performed on pre-coated Merck silica gel 60 F254 and Merck RP-18 F254 plates. 
All the reported yields refer to isolated yields. The compounds were analyzed for purity (HPLC) 
using a Agilent 1200 HPLC system equipped with Quat pump (G1311B), injector (G1329B) 
1260 ALS, TCC 1260 (G1316A) and detector 1260 DAD VL + (G1315C) (other details are 
presented in the Supplementary material to this paper). All compounds were >95 % pure. 
The analytical and spectral data of the synthesized compounds are given in the Supple-
mentary material to this paper. 
Chemistry 
General procedure. 5-(4-Methylphenyl)furan-2-carbaldehyde (4).6 In a dry glass flask 
purged with argon, Pd(OAc)2 (3.4 mg, 0.015 mmol) was dissolved in dry dimethoxyethane 
(DME) (2 mL) and PPh3 (16.2 mg, 0.060 mmol) was added. The resultant solution was stirred 
at room temperature for 10 min and 3 (113.8 mg, 0.650 mmol) and Na2CO3 (aq.) (2M, 0.65 
mL, 1.3 mmol) were added. After 5 min stirring at room temperature, a solution of (4-methyl-
phenyl)boronic acid (111.5 mg, 0.820 mmol) was added and the reaction mixture was purged 
with argon and refluxed at 90 °C overnight under argon. The solution was cooled to room 
temperature and filtered through a Celite pad, washed with CH2Cl2 and dried with anh. 
Na2SO4. The organic solvent was removed under reduced pressure and the crude product was 
purified by dry-flash chromatography (SiO2: hexane/EtOAc = 95/5 to 9/1) to afford the title 
compound 4 (113.6 mg, 94 %). 
5-(4-Bromophenyl)furan-2-carbaldehyde (5).7 To a glass flask, 3 (113.8 mg, 0.650 
mmol), (4-bromophenyl)boronic acid (143.6 mg, 0.715 mmol), tetrabutylammonium bromide 
(209.6 mg, 0.650 mmol), Pd(OAc)2 (2.9 mg, 0.013 mmol) and K2CO3 (224.6 mg, 1.63 mmol) 
were added and then dissolved in deionized water (3 mL). The reaction mixture was stirred 
vigorously for 5 h at room temperature. After the white reaction mixture had become yellow 
and non-homogeneous, the mixture was diluted with water (10 mL), and the product was 
extracted with EtOAc. The organics were separated, filtered through a Celite pad, and dried 
with MgSO4. The organic solvent was removed under reduced pressure and the crude product 
was purified by dry-flash chromatography (SiO2: hexane/EtOAc = 9/1 to 7/3) to afford the 
title compound 5 (11 mg, 7 %). 
5-(4-Fluorophenyl)furan-2-carbaldehyde (6).6 The general Suzuki coupling procedure 
was followed, except 4-fluorophenylboronic acid (114.7 mg) was used. The reaction mixture 
was refluxed for 12 h. The crude product was purified by dry-flash chromatography (SiO2: 
hexane/EtOAc = 95/5 to 8/2) to afford the title compound 6 (108.3 mg, 88 %). 
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5-(4-Methoxyphenyl)furan-2-carbaldehyde (7).6 The general Suzuki coupling procedure 
was followed, except 4-methoxyphenylboronic acid (124.6 mg) was used. The reaction mix-
ture was refluxed for 12 h. The crude product was purified by dry-flash chromatography 
(SiO2: hexane/EtOAc = 9/1 to 6/4) to afford the title compound 7 (118 mg, 90%). 
4-Bromo-5-phenylthiophene-2-carbaldehyde (10).5 To a solution of aldehyde 8 (76 mg, 
0.40 mmol) in dry CHCl3 (700 μL) was added a solution of bromine (33 μL, 0.64 mmol) in 
dry CHCl3 (330 μL). The resulting solution was stirred at r.t. for 3 h. To the reaction mixture 
was added sat. Na2S2O3 solution and the reaction mixture extracted with CH2Cl2 (2×10 mL). 
The organic layer was washed with sat. NaHCO3 solution and brine and dried over anhydrous 
Na2SO4. The organic solvent was removed under reduced pressure and the crude residue was 
purified by dry-flash chromatography (SiO2: hexane/EtOAc = 9/1) to yield 10 (81 mg, 75 %). 
4-Bromo-5-phenyl-2-furaldehyde (11).8 To a solution of aldehyde 9 (100 mg, 0.58 
mmol) in MeCN (10 mL) was added NBS (114 mg, 0.64 mmol). The resulting solution was 
stirred at r.t. for 24 h. To the reaction mixture was added H2O (10 mL) and the reaction mix-
ture was extracted with CH2Cl2 (2×10 mL). The organic layer was washed with brine and 
dried over anhydrous Na2SO4. The organic solvent was removed under reduced pressure and 
the crude residue was purified by dry-flash chromatography (SiO2: hexane/EtOAc = 95/5) to 
yield 11 (72.9 mg, 50 %). 
4,5-Diphenylthiophene-2-carbaldehyde (12).6 The general Suzuki coupling procedure 
was followed, except phenylboronic acid (38.3 mg) was used. The reaction mixture was ref-
luxed for 12 h. The crude product was purified by dry-flash chromatography (SiO2: hex-
ane/EtOAc = 9/1) to afford the title compound 12 (53 mg, 89 %). 
4-(4-Fluorophenyl)-5-phenylthiophene-2-carbaldehyde (13). The general Suzuki coup-
ling procedure was followed, except 4-fluorophenylboronic acid (36.6 mg) was used. The 
reaction mixture was refluxed for 12 h. The crude product was purified by dry-flash chroma-
tography (SiO2: hexane/EtOAc = 9/1) to afford the title compound 13 (42 mg, 77 %). 
2-(4-Bromo-5-phenyl-2-furyl)-1,3-dioxolane (14). Aldehyde 11 (117 mg, 0.46 mmol), 
ethylene glycol (130 μL, 2.33 mmol), and p-toluenesulfonic acid monohydrate (1.8 mg, 
9.32×10-3 mmol) were dissolved in PhMe (4 mL). Under Dean–Stark conditions, the reaction 
mixture was refluxed for 3h, and then washed sequentially three times with 3 M NaOH and 
water. The PhMe layer was dried, filtered, evaporated under vacuum and the crude residue 
was purified by dry-flash chromatography (SiO2: hexane/EtOAc = 9/1) to yield acetal 14 (109 
mg, 80 %). 
4-Fluoro-5-phenyl-2-furaldehyde (15). To a solution of acetal 14 (49 mg, 0.167 mmol) in 
dry THF (2.5 mL), nBuLi (1.6 M in hexane, 125 μL, 0.2 mmol) was added dropwise at a 
temperature below –60 °C under Ar. After stirring the mixture for 2 h, N-fluorobenzenesul-
fonimide (58 mg, 0.18 mmol) in THF (1 mL) was added dropwise. The reaction mixture was 
allowed to warm to room temperature. H2O was added to the reaction mixture, which was 
then extracted with CH2Cl2, washed with brine, dried with MgSO4 and concentrated. To a 
stirred solution of crude residue in THF (2 mL) at 25 °C was added 2M HCl (0.6 mL), and the 
reaction mixture was stirred at 25 °C for 1 h. The reaction mixture was slowly quenched with 
sat. aq. NaHCO3 (2 mL), the biphasic mixture was extracted with CH2Cl2 (2×10 mL), and the 
combined organic layers were dried over MgSO4 and concentrated. The crude residue was 
purified by dry-flash chromatography (SiO2: hexane/EtOAc = 9/1) to yield 15 (9.4 mg, 30 % 
for 2 steps). 
(4-Nitro-5-phenyl-2-thienyl)methylene diacetate (16). To a cold solution of aldehyde 8 
(35 mg, 0.186 mmol) in Ac2O (500 μL) was added a solution of HNO3 (9.5 μL, 0.223 mmol) 
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in AcOH (190 μL). The resulting solution was stirred at r.t. for 2 h, and then ice was added 
and the reaction mixture was extracted with CH2Cl2 (2×10 mL). The organic layer was 
washed with sat. NaHCO3 solution, brine and dried over anhydrous Na2SO4. The organic sol-
vent was removed under reduced pressure and the crude residue was purified by dry-flash 
chromatography (SiO2: hexane/EtOAc = 8/2) to yield 14 (44 mg, 71 %). 
4-Nitro-5-phenylthiophene-2-carbaldehyde (17). To a solution of diacetate 16 (17 mg, 
0.05 mmol) in MeOH/H2O (1/1volume ratio, 1 mL), was added H2SO4 (100 µL). The 
resulting solution was stirred at r.t. for 2 h, and then H2O was added and the reaction mixture 
extracted with CH2Cl2 (2×10 mL). The organic layer was washed with brine and dried over 
anhydrous Na2SO4. The organic solvent was removed under reduced pressure and the crude 
product was used in the next step. 
General procedure for the preparation of guanylhydrazones.4 (2E)-2-{[5-(4-Methylphe-
nyl)furan-2-yl]methylidene}hydrazinecarboximidamide hydrochloride (18). To a solution of 
aldehyde 4 (86.2 mg, 0.463 mmol) in absolute ethanol (10 mL), aminoguanidine hydro-
chloride (51.2 mg, 0.463 mmol) was added. The resultant solution was stirred at room tem-
perature for 5 min, and a solution of concentrated HCl (5 mol %) in absolute EtOH (50 µL, 
1/25, v/v) was added. The reaction mixture was heated to 90 °C, refluxed for 18 h and allowed 
to cool to room temperature. The solvent was removed under reduced pressure, the crude pro-
duct was washed with CH2Cl2 (1 mL) and then crystallized from EtOH/hexane (9/1) to pro-
vide the title compound 18 (127.8 mg, 99 %). 
(2E)-2-{[5-(4-Methoxyphenyl)furan-2-yl]methylidene}hydrazinecarboximidamide hydro-
chloride (19). Following the general procedure for guanylhydrazone formation, 19 (144 mg, 
100 %) was obtained from 7. 
(2E)-2-{[5-(4-Fluorophenyl)furan-2-yl]methylidene}hydrazinecarboximidamide hydro-
chloride (20). Following the general procedure for guanylhydrazone formation, 20 (93.2 mg, 
100 %) was obtained from 6. 
(2E)-2-{[5-(4-Bromophenyl)furan-2-yl]methylidene}hydrazinecarboximidamide hydro-
chloride (21). Following the general procedure for guanylhydrazone formation, 21 (17.2 mg, 
100 %) was obtained from 5. 
(2E)-2-[(4-Fluoro-5-phenyl-furan-2-yl)methylidene]hydrazinecarboximidamide hydro-
chloride (22). Following the general procedure for guanylhydrazone formation, 22 (7.1 mg, 79 
%) was obtained from 15. 
(2E)-2-[(4-Bromo-5-phenyl-2-thienyl)methylidene]hydrazinecarboximidamide hydro-
chloride (23). Following the general procedure for guanylhydrazone formation, 23 (41 mg, 92 
%) was obtained from 10. 
(2E)-2-[(4-Bromo-5-phenyl-furan-2-yl)methylidene]hydrazinecarboximidamide hydro-
chloride (24). Following the general procedure for guanylhydrazone formation, 24 (44 mg, 78 
%) was obtained from 11. 
(2E)-2-[(4-Nitro-5-phenyl-2-thienyl)methylidene]hydrazinecarboximidamide hydrochlo-
ride (25). Following the general procedure for guanylhydrazone formation, 25 (19.5 mg, 75 
%) was obtained from 17. 
(2E)-2-[(4,5-Diphenyl-2-thienyl)methylidene]hydrazinecarboximidamide hydrochloride 
(26). Following the general procedure for guanylhydrazone formation, 26 (51.9 mg, 99%) was 
obtained from 12. 
(2E)-2-{[4-(4-Fluorophenyl)-5-phenyl-2-thienyl]methylidene}hydrazinecarboximidamide 
hydrochloride (27). Following the general procedure for guanylhydrazone formation, 27 (36.5 
mg, 92%) was obtained from 13. 
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Antimicrobial activity 
Guanylhydrazones were dissolved in DMSO in stock concentrations of 50 mg mL-1 and 
used immediately for antimicrobial activity assessments. MIC concentrations (concentration 
value corresponding to the lowest concentration that inhibited the growth after 24 h at 37 °C) 
were determined according to the standard broth microdilution assays, recommended by the 
National Committee for Clinical Laboratory Standards (M07-A8) for bacteria in LB (Luria- 
-Bertani) broth and Standards of European Committee on Antimicrobial Susceptibility Testing 
(EDef7.1.) in SAB (Sabouraud Dextrose) broth. The highest concentration used was 500 µg 
mL-1. The test organisms included Pseudomonas aeruginosa PAO1 (NCTC 10332), Staphylo-
coccus aureus (ATCC 25923), Micrococcus luteus (ATCC 379), Listeria monocytogenes 
(NCTC 11994) Candida albicans (ATCC 10231), Issatchenkia orientalis (ATCC 6258) and 
Candida parapsilosis (ATCC 22019). The inoculums were 105 colony forming units, CFU 
mL-1, for the bacteria and 104 CFU mL-1 for the Candida strains. 
CONCLUSIONS 
In the present work, an efficient synthesis of novel guanylhydrazones was 
designed. The activity of these compounds against the panel of human pathogens 
consisting of one Gram-negative strain, three Gram-positive strains, and three 
fungal strains, was assessed. Noticeably, compounds 26 and 27 showed excellent 
antibacterial activities against Gram-positive S. aureus ATCC 25923 and M. lut-
eus ATCC 379, even better than the control drug, kanamycin. Furthermore, com-
pounds 26 and 27 displayed good antifungal activity against C. parapsilosis 
ATCC 22019. Altogether, the reported results indicate that the selected guanyl-
hydrazones could form the basis for further development of new and effective 
antimicrobial agents.  
SUPPLEMENTARY MATERIAL 
Analytical and spectral data of the synthesized compounds are available at the pages of 
journal website: http://www.shd.org.rs/JSCS/, or from the corresponding author on request. 
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И З В О Д  
АНТИБАКТЕРИЈСКА И АНТИФУНГАЛНА АКТИВНОСТ ГВАНИЛХИДРАЗОНСКИХ 
ДЕРИВАТА 
ВЛАДИМИР АЈДАЧИЋ1, ЈЕЛЕНА ЛАЗИЋ1, МАРИЈА МОЈИЋЕВИЋ2, САНДРА ШЕГАН3, 
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У овом раду приказана је синтеза серије гуванилхидразонских деривата. Добијеним 
дериватима испитана је антибактеријска и антифунгална активност. Утврђено је да једи-
њења 26 и 27 показују изражену антибактеријску активност према Staphylococcus aureus 
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ATCC 25923 и Micrococcus luteus ATCC 379 сојевима. Истовремено, ова једињења пока-
зала су и изражену антифунгалну активност према Candida parapsilosis ATCC 22019 соју. 
(Примљено 13. фебруара, ревидирано 3. марта, прихваћено 7. марта 2017) 
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